Literature DB >> 10638490

Phase II trial of suramin in patients with metastatic renal cell carcinoma.

R Dreicer1, D C Smith, R D Williams, W A See.   

Abstract

This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only 3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10638490     DOI： 10.1023/a:1006331518952

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  10 in total

Review 1.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

2.  Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

Authors:  M E Gleave; M Elhilali; Y Fradet; I Davis; P Venner; F Saad; L H Klotz; M J Moore; V Paton; A Bajamonde
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

3.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

Authors:  S Negrier; B Escudier; C Lasset; J Y Douillard; J Savary; C Chevreau; A Ravaud; A Mercatello; J Peny; M Mousseau; T Philip; T Tursz
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

Review 4.  Suramin: with special reference to onchocerciasis.

Authors:  F Hawking
Journal:  Adv Pharmacol Chemother       Date:  1978

Review 5.  Surgery of renal cell carcinoma.

Authors:  D R Couillard; R W deVere White
Journal:  Urol Clin North Am       Date:  1993-05       Impact factor: 2.241

6.  A pilot study of suramin in the treatment of metastatic renal cell carcinoma.

Authors:  R V La Rocca; C A Stein; R Danesi; M R Cooper; M Uhrich; C E Myers
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

7.  Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

Authors:  M A Eisenberger; L M Reyno; D I Jodrell; V J Sinibaldi; K H Tkaczuk; R Sridhara; E G Zuhowski; M H Lowitt; S C Jacobs; M J Egorin
Journal:  J Natl Cancer Inst       Date:  1993-04-21       Impact factor: 13.506

8.  Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Authors:  R J Motzer; D M Nanus; P O'Moore; H I Scher; D F Bajorin; V Reuter; W P Tong; J Iversen; C Louison; A P Albino
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

9.  Suramin: an anticancer drug with a unique mechanism of action.

Authors:  C A Stein; R V LaRocca; R Thomas; N McAtee; C E Myers
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

10.  Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.

Authors:  L M Reyno; M J Egorin; M A Eisenberger; V J Sinibaldi; E G Zuhowski; R Sridhara
Journal:  J Clin Oncol       Date:  1995-09       Impact factor: 44.544
  10 in total
  9 in total

1.  Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.

Authors:  Maryam B Lustberg; Shubham Pant; Amy S Ruppert; Tong Shen; Yong Wei; Ling Chen; Lisa Brenner; Donna Shiels; Rhonda R Jensen; Michael Berger; Ewa Mrozek; Bhuvaneswari Ramaswamy; Michael Grever; Jessie L Au; M Guillaume Wientjes; Charles L Shapiro
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-22       Impact factor: 3.333

2.  Suramin affects coupling of rhodopsin to transducin.

Authors:  Nicole Lehmann; Gopala Krishna Aradhyam; Karim Fahmy
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

3.  Suramin as a chemosensitizer: oral pharmacokinetics in rats.

Authors:  Adam Ogden; M Guillaume Wientjes; Jessie L S Au
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

4.  Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.

Authors:  Ze Lu; Trini S-S Wientjes; Jessie L-S Au
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

5.  Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.

Authors:  Saby George; Robert Dreicer; Jessie J L Au; Tong Shen; Brian I Rini; Susan Roman; Matthew M Cooney; Tarek Mekhail; Paul Elson; Guillaume M Wientjes; Ram Ganapathi; Ronald M Bukowski
Journal:  Clin Genitourin Cancer       Date:  2008-09       Impact factor: 2.872

6.  A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.

Authors:  Sahra Borges; Heike R Döppler; Peter Storz
Journal:  Breast Cancer Res Treat       Date:  2014-02-08       Impact factor: 4.872

7.  Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.

Authors:  Elaine T Lam; Jessie L-S Au; Gregory A Otterson; M Guillaume Wientjes; Ling Chen; Tong Shen; Yong Wei; Xiaobai Li; Tanios Bekaii-Saab; Anthony J Murgo; Rhonda R Jensen; Michael Grever; Miguel A Villalona-Calero
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-28       Impact factor: 3.333

Review 8.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

9.  Manipulating Active Structure and Function of Cationic Antimicrobial Peptide CM15 with the Polysulfonated Drug Suramin: A Step Closer to in Vivo Complexity.

Authors:  Mayra Quemé-Peña; Tünde Juhász; Judith Mihály; Imola Cs Szigyártó; Kata Horváti; Szilvia Bősze; Judit Henczkó; Bernadett Pályi; Csaba Németh; Zoltán Varga; Ferenc Zsila; Tamás Beke-Somfai
Journal:  Chembiochem       Date:  2019-05-20       Impact factor: 3.164
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.